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Abstract: PAPA syndrome (Pyogenic Arthritis, Pyoderma gangrenosum, and Acne) is an autosomal dominant, hereditary 
auto-inflammatory disease arising from mutations in the PSTPIP1/CD2BP1 gene on chromosome 15q. These mutations 
produce a hyper-phosphorylated PSTPIP1 protein and alter its participation in activation of the “inflammasome” involved 
in interleukin-1 (IL-1) production. Overproduction of IL-1 is a clear molecular feature of PAPA syndrome. Ongoing re-
search is implicating other biochemical pathways that may be relevant to the distinct pyogenic inflammation of the skin 
and joints characteristic of this disease. This review summarizes the recent and rapidly accumulating knowledge on these 
molecular aspects of PAPA syndrome and related disorders. 
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INTRODUCTION  
The auto-inflammatory disorders bear resemblance to 
classic autoimmune diseases such as systemic lupus in that 
they present with seemingly unprovoked inflammation but, 
unlike most autoimmune diseases, high-titer auto-antibodies 
or antigenic-specific T lymphocytes are not found [1-3]. 
Considered broadly, this disease class is characterized by 
abnormalities in the innate immune system. Familial Medi-
terranean Fever (FMF), a recessive disorder caused by muta-
tions in the gene encoding the pyrin protein, is the founding 
member of this disease class [3] that is marked by episodic 
inflammation of serosal or synovial tissue, fever, and occa-
sional lesions of the skin. Many disorders are now recog-
nized as auto-inflammatory. Some, like FMF, display simple 
Mendelian inheritance and are caused by mutations in single 
genes [2-4]. Examples include TNF receptor-associated peri-
odic syndrome (TRAPS) [2], hyperimmunoglobulinemia D 
with periodic fever syndrome (HIDS) [5, 6], familial cold 
auto-inflammatory syndrome (FCAS)/Muckle-Wells syn-
drome (MWS), neonatal onset multisystem inflammatory 
disease (NOMID) [7], deficiency of the interleukin-1-
receptor antagonist (DIRA) [8, 9]; the granulomatous dis-
eases such as Blau syndrome [10], early onset sarcoidosis 
[11], and chronic granulomatous disease (CGD) [12]; and 
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the pyogenic disorders Majeed syndrome [13] and PAPA 
syndrome [14]. Auto-inflammatory underpinnings are now 
also recognized in common, less heritable conditions includ-
ing Crohn’s disease and systemic-onset juvenile idiopathic 
arthritis (SoJIA) [15-17]. Over the past decade our under-
standing of both the clinical characteristics and molecular 
pathogenesis of the auto-inflammatory diseases has ex-
panded dramatically (for an extensive review of this disease 
class please see reference [3]). Accordingly, a new classifi-
cation system was recently proposed that defines auto-
inflammatory disease by one of six categories according to 
its underlying molecular pathology [3]. The chronicle of 
PAPA syndrome, a relatively recent addition and one of the 
more clinically dramatic members of the auto-inflammatory 
disease family, is a relevant illustration of diagnostic, mo-
lecular, and clinical advances in the field. In this review we 
summarize the ongoing elucidation of PAPA syndrome 
pathogenesis, with particular regard to the impact of molecu-
lar discovery on the diagnosis and management of affected 
patients and families.  
CLINICAL CHARACTERISTICS OF PAPA SYN-
DROME  
PAPA syndrome (OMIM #604416) was described as a 
heritable disease in an extended family in 1997 [14]. We 
now appreciate that PAPA syndrome was in fact first re-
ported in a single male patient described with “streaking 
leukocyte factor”, arthritis, and pyoderma gangrenosum in 
1975 [18]. “Streaking leukocyte factor” referred to a partially 
purified, ~160 kd component of this patient’s serum that 
enhanced the random migration of normal mononuclear cells 520    Current Genomics, 2010, Vol. 11, No. 7  Smith et al. 
and neutrophils in laboratory studies. (The identity of this 
“factor” is unresolved.) Both reports described joint inflam-
mation as generally responsive to high dose corticosteroids. 
A second extended family was described in 2000 as “familial 
recurrent arthritis” [19]. Additional families and cases are 
now reported (described later in this review). Distinguishing 
features of PAPA syndrome include early onset, florid, and 
painful flares of recurrent sterile arthritis involving a promi-
nent neutrophilic infiltrate, and autosomal dominant inheri-
tance. Skin involvement is more variable and may present as 
ulcerations, frank pyoderma gangrenosum, or severe cystic 
acne (Fig. 1). Standard laboratory findings typically reflect 
systemic inflammation but are otherwise non-diagnostic; 
however elevated production of interleukin-1 beta (IL-1) 
and tumor necrosis factor (TNF) in peripheral blood leuko-
cytes has been reported in more recent literature [20-22]. 
Symptoms persist into adulthood, with a natural history of 
significant joint destruction. Anecdotally, some individuals 
report significant psycho-social impairment due to physical 
disability, steroid-induced Cushingoid appearance, and per-
manent, wide-spread cutaneous scarring.  
PSTPIP1 / CD2BP1 
Positional cloning methods subsequently identified co-
segregating missense mutations in the proline-serine-
threonine phosphatase-interacting protein 1 gene (PSTPIP1, 
also known as CD2 binding protein 1 (CD2BP1)) in the 
original family that defined the syndrome and a second ex-
tended family (originally described with “familial recurrent 
arthritis”) [23-24]. Other PAPA syndrome patients with ei-
ther of these PSTPIP1 mutations have been reported more 
recently [25, 26]. Specifically, missense mutations 
(c.904G>A) or (c.964G>C) occur in exons 10 and 11, creat-
ing A230T or E250Q variants, respectively, in affected indi-
viduals. The observation of the same mutation in seemingly 
unrelated families suggest either a founder effect, particu-
larly as these were each observed in cases within the same 
 
Fig. (1). Pyoderma gangrenosum in a child with PAPA syndrome. 
Table 1. Summary of PSTPIP1 Mutation Screening for Cases of Putative PAPA Syndrome. Cases were screened in the order given. The 
last three cases were accepted for screening based on the presence of three or more features of PAPA syndrome. *Exons 10 and 11 
only were screened. 
Subject 
Country of 
Origin 
Sex  Family History  Onset  Clinical Characteristics 
PSTPIP1  
Mutation 
1  Spain  M  affected brother, mother  Child  arthritis; psoriasis; pyoderma gangrenosum 
A230T (confirmed 
in affected brother) 
2  Italy  M  mother mildly affected  Child  “consistent with PAPA syndrome”  Negative 
3 USA  M  negative  Adult 
inflammations around surgical incisions-pyoderma gangrenosum? 
Subsequent severe bleeding. Responsive to cortico-steroids 
Negative 
4 USA  F 
multiple individuals with 
reported arthritis, fibromy-
algia, diabetes mellitus 
7 
severe pauci-articular corticosteroid responsive arthritis; recurrent 
destructive pyoderma gangrenosumat age 11; recent dep venous 
thrombosis, pulmonary hypertension and congestive heart failure 
None detected in 
screens of exon 10 
or 11 
5 Canada  M 
undetermined; father’s 
history incomplete 
1 
Recurrent sterile pyogenic arthritis in knee; fever, synovial expan-
sion into muscle above and below knee 
A230T 
6 
New 
Zealand 
M 
positive with apparent 
dominant inheritance 
1.5  Recurrent pyogenic arthritis 
E250Q (confirmed 
in affected parent) 
7 USA  M 
mother with positive ANA 
and acne 
14 
arthritis in fingers, toes, and large joints; severe acne; ulcerated 
lesions bilaterally on hands, forearms, elbows described as pyo-
derma gangrenosum; aphthous ulcers; negative laboratory findings 
None detected in 
screens of exons 
10 and 11 
8 
France (Tou-
louse) 
M negative  ? 
recurrent arthritis of knees; painful involvement of chest, lower 
back, and sacrum regions; acute episodic abdominal pain and 
fever; severe cystic acne; recurrent pyoderma of axillae, groin, and 
face 
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ethnic group, i.e. European descent, or a mutational hotspot. 
Otherwise, two additional missense mutations are reported, 
both in exon 11 and creating E250K or D260N amino acid 
changes. This genotype and phenotype information is docu-
mented and continuously updated for PAPA syndrome and 
the other auto-inflammatory diseases within the INFEVERS 
database, a web-based resource (please see 
http://fmf.igh.cnrs.fr/  
ISSAID/infevers/) [17]. It is interesting that other putative 
cases of PAPA syndrome have proven negative for PSTPIP1 
coding or splicing mutations (Table 1) [our unpublished data 
and reference 27]. This suggests the possibility that altera-
tions in other gene(s) could evoke features of PAPA syn-
drome. Notably, also, cases with isolated pyoderma gan-
grenosum or Crohn’s disease-associated pyoderma gan-
grenosum, have thus far proven negative for PSTPIP1 muta-
tions. However, recently a CCTG repeat in the PSTPIP1 
promoter of patients with Crohn’s disease or aseptic ab-
scesses syndrome was identified [28] that may play a patho-
genic role in these diseases. CD2BP1  (PSTPIP1) and 
CARD15 mutations are not associated with pyoderma gan-
grenosum in patients with inflammatory bowel disease 
(Table 1) [29]. Further study is required to explain PSTPIP1 
mutation-negative cases of putative PAPA syndrome. In the 
meantime, the low complexity of disease-associated muta-
tions in PSTPIP1 simplifies diagnostic screening for patients 
with a tentative diagnosis of PAPA syndrome, and a DNA 
sequence-based test for PSTPIP1 coding mutations is now 
commercially available. It is worth noting that the PAPA-
associated mutations presently identified are highly predic-
tive, as reflected by the essentially complete disease pene-
trance they confer, and thus provide useful information in the 
context of genetic counseling for families. 
Interestingly, there is a homolog of PSTPIP1, named 
proline-serine-threonine-phosphatase-interacting protein 2 
(PSTPIP2), encoded on chromosome 18 in both humans and 
the mouse. PSTPIP1 and PSTPIP2 predicted proteins share 
approximately 41% amino acid identity, but PSTPIP2 is 
lacking the terminal src-homology 3 (SH3) domain found in 
PSTPIP1 (Fig. 2) [30]. At present it is unclear if PSTPIP1 
and PSTPIP2 are completely distinct, or if they participate in 
overlapping biochemical pathways. Both proteins possess 
Fer-CIP4 and coiled-coil domains involved in binding with 
PEST-type phosphatases. Fer-CIP4 domains also bind phos-
phatidyl inositol (4, 5) bisphosphonate (PI(4,5)P2) on artifi-
cial liposomes with high affinity, inducing membrane tubula-
tion and suggesting that both could participate in coupling 
membrane deformation to cytoskeletal reorganization (de-
scribed in more detail below) [31]. Several lines of evidence 
link PSTPIP2 with yet another auto-inflammatory condition. 
In the mouse, spontaneous recessive mutations in PSTPIP2 
produce a phenotype most closely resembling human chronic 
multifocal osteomyelitis (CRMO), another auto-
inflammatory disease of bone and skin. Human PSTPIP1 is 
encoded on chromosome 18q21.3-22 and overlaps a suscep-
tibility locus for CRMO [32]. Based on these observations, 
PSTPIP2 could be an attractive candidate gene for cases with 
PAPA-like features that are negative for PSTPIP1 mutations, 
however, no mutations have been identified. Further func-
tional studies, particularly utilizing PSTPIP2 mouse mutants, 
will provide insight into the biochemical, and possibly clini-
cal relationship of these two proteins.  
PSTPIP1 BINDING PROTEINS  
PSTPIP1 is a cytoskeletal adaptor protein that was origi-
nally identified in the mouse through its interaction with 
PEST (rich in proline (P), glutamic acid (E), serine (S), and 
threonine (T) residues)-type protein tyrosine phosphatase 
(PTP-PEST, also known as PTPN12) [33]. The human ho-
molog, called CD2BP1, was identified near the same time by 
interaction with the T cell surface protein CD2 [34]. The 
gene and protein are now generally cited as “PSTPIP1”. The 
fact that PAPA syndrome mutations clustered in the coiled-
coil region of the protein immediately cast suspicion that the 
PTP-PEST interaction mediated through this domain was 
central to pathology. Indeed, the E250Q and A230T variants 
of PSTPIP1 were shown to severely abrogate binding to 
PTP-PEST in yeast two hybrid and co-immunoprecipitation 
 
Fig. (2). PSTPIP1 protein schematic. FCH, coiled-coil, and SH3 domains are shown. Asterisks denote the relative positions of the A230T 
and E250Q mutations. Interacting proteins are shown below single domains for simplicity. It should be noted that some in vitro studies indi-
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experiments [21, 24]. At least one consequence of this is 
hyperphosphorylation of PSTPIP1 itself. Tryptic peptide 
mapping identified tyrosine 344 as a primary phosphoryla-
tion site of PSTPIP1. Experiments using a combination of 
co-transfection, immunoprecipitation and anti-phospho-
tyrosine antibody western blots have shown that binding of 
PTP-PEST to PSTPIP1 is essential for its dephosphorylation 
[21, 35, 36]. Interestingly, PTP-PEST
/ fibroblasts contain 
hyperphosphorylated PSTPIP1 and a defect in cytokinesis 
[35].  
PSTPIP1 is highly expressed in hematopoietic cells, and 
the protein interacts with other immune-related proteins in 
addition to CD2 and PTP-PEST. These include Wiskott Ald-
rich Syndrome protein (WASP), c-Abl kinase, and Fas 
ligand (FasL) [36-38]. Cumulative evidence suggests that 
each of these proteins acts as a “substrate”, binding primarily 
via the PSTPIP1 SH3 domain (Fig. 2) to be delivered to 
PTP-PEST (or homolog) for de-phosphorylation [39-41]. It 
is not obvious whether A230T or E250Q mutations directly 
alter these interactions, or may mediate effects due to hyper-
phosphorylation of the “substrate” or of PSTPIP1 itself. For 
example, the PSTPIP1/WASP interaction is phosphoryla-
tion-dependent, and disease mutations consequently predict 
reduced interaction in vivo. Thus WASP-mediated cytoskele-
tal reorganization events are implicated in PAPA pathogene-
sis via post-translational mechanisms [24, 36]. In the case of 
FasL, it is clear that this protein forms a ternary complex 
with PSTPIP1/PTP-PEST, and that PSTPIP1 mediates its 
sequestration away from the cell surface and into intracellu-
lar secretory lysosomes [38, 39]. This suggests a general 
inhibitory effect on cytotoxic T cell functioning. Further 
study will elucidate the effects of PAPA causative mutations 
on these interactions and their relationship to manifestations 
of the disease (see more discussion later in this review). 
Taken altogether, current knowledge suggests multiple func-
tions for a PSTPIP1/PTP-PEST complex in hematopoietic 
cells that may have direct consequences for immune cell 
adhesion, invasion, and migration [36-46]. It is worth noting 
that PSTPIP1 also interacts with other PTP-PEST homologs 
such as PTP hematopoietic stem cell factor (HSCF) [33], 
suggesting possible roles in functions such as lymphocyte 
activation, antigen processing, granule exocytosis, phagocy-
tosis and apoptosis, as the PEST family phosphatases have 
been implicated in these processes [47].  
PSTPIP1 also binds itself. Western blots of patient and 
control monocyte lysates run on native gels clearly revealed 
a major band twice the size of PSTPIP1 monomer when 
probed with an anti-PSTPIP1 polyclonal antibody. Weaker 
bands possibly corresponding to PSTPIP1 trimers or tetram-
ers were also observed [48]. In silico modeling predicted that 
the dimerized protein assumes a gently curved structure that 
is not altered by disease-causing mutations. Other work has 
suggested the PSTPIP1 exists as a homotrimer [49]. Either 
way, evidence suggests that disease-causing mutations in 
PSTPIP1 do not alter its self-binding capacity.  
PSTPIP1 AND PYRIN  
As noted earlier, mutations in the pyrin protein are re-
sponsible for FMF, a disease that shows some clinical simi-
larities to PAPA syndrome, including a neutrophil-rich ster-
ile infiltrate of the joints, neutrophilic dermatoses, and ele-
vated production of IL-1 by peripheral blood leukocytes [50-
52]. The relationship of these two diseases was clarified by 
the discovery of molecular overlap, when a pyrin bait identi-
fied PSTPIP1 in yeast two hybrid screens of a monocyte 
library. Subsequent work confirmed the direct interaction of 
pyrin and PSTPIP1. Furthermore, hyperphosphorylated vari-
ants of PSTPIP1 (e.g. containing disease-causing mutations) 
displayed a higher affinity for pyrin than wild type forms 
[21]. This discovery was a watershed moment, as it linked 
the two diseases within the same previously described path-
way and suggested a perturbation that could be targeted   
therapeutically. Specifically, pyrin has been proposed to ac- 
tivate IL-1 production via a complex known as the “in- 
flammasome”. Although the composition of inflammasomes  
may vary, for the purposes of this discussion we focus on a  
canonical complex of three proteins: NLRP3/ASC/Caspase- 
1. NLRP3, also called cryopyrin, contains a pyrin-like do- 
main through which it interacts with apoptosis-associated   
speck-like protein with a caspase recruitment domain (ASC).  
ASC in turn interacts with caspase 1 that catalytically   
cleaves pro-IL-1 into its active form. Upon activation, the  
inflammasome complex cleaves pro-IL-1 to produce ma- 
ture IL-1 that is subsequently secreted, perhaps through a 
pathway of lysosome exocytosis [53, 54]. Mutations in 
NLRP3  itself cause the auto-inflammatory syndromes 
FCAS/MWS/NOMID described earlier. How pyrin partici-
pates in this or other inflamma-somes is the subject of ongo-
ing investigations. However, the experiments of Shoham   
et al. clearly demonstrated overproduction of IL-1 in the 
presence of PAPA-associated mutations relative to wild type 
in a heterologous, reconstituted system, as well as elabora-
tion of IL-1 in lipopolysaccharide (LPS)-stimulated mono-
cytes of a PAPA syndrome patient [21]. IL-1 precursor 
transcripts are also highly over-expressed in circulating neu-
trophils from PAPA syndrome patients as compared to 
healthy control individuals by transcript profiling (our un-
published observations).  
More recent studies have suggested an alternative 
mechanism in which the balance of interaction between 
PSTPIP1, pyrin and ASC is altered by PSTPIP1 variants 
E250Q and A230T in monocytes, leading to activation of the 
so-called “pyroptosome” that leads to cell death and release 
of cytokines such as IL-1 [49, 55]. PSTPIP1 associates with 
microtubules in native and transfected cells and does not 
associate with the ASC compartment in the absence of pyrin 
[48, 49]. Pyrin modulates PSTPIP1 intracellular distribution 
and is apparently necessary for PSTPIP1-mediated regula-
tion of the ASC pyroptosome. Importantly, either “inflam-
masome” or “pyroptosome” mechanisms predict overpro-
duction of IL-1 in the presence of PAPA causal mutations 
(Fig. 3). It is worth noting that while such disease-causing 
mutations affect pyrin-mediated pathways, the reverse is 
apparently not the case, i.e. FMF causal mutations do not 
affect binding to PSTPIP1. This is generally explained by the 
fact that such mutations almost always occur in pyrin outside 
the PSTPIP1 binding site, a B box domain that mediates 
pyrin autoinhibition in the absence of PSTPIP1 [56]. Two B 
box variants, P369S and R408Q, may play a role in FMF 
susceptibility but do not appear to alter PSTPIP1 interaction 
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PAPA SYNDROME AS AN “INFLAMMASOMOPA-
THY” 
Studies described above firmly established PAPA syn-
drome as a member of the auto-inflammatory disease family, 
and more specifically, an “inflammasomopathy” according 
to the new classification system proposed by Masters et al. 
[3]. IL-1 hence emerged as a prime therapeutic target for 
PAPA syndrome. Fortunately, biological agents that target 
this cytokine cascade are available. Anakinra, a recombinant 
IL-1 receptor antagonist that is administered by daily par-
enteral injection, has proven to be effective in controlling 
flares for PAPA syndrome patients [57, 58]. Indeed, in our 
experience, this treatment is very effective in resolving joint 
inflammation altogether for some patients.  
Pharmaceuticals that target downstream events in IL-1 
signaling may also prove effective in some patients. For ex-
ample, IL-1 is a potent inducer of TNF, a major stimulant 
of apoptosis and inflammation, and an anti-TNF mono-
clonal antibody, infliximab, has shown promising results in 
controlling symptoms of PAPA syndrome, including dra-
matic resolution of severe pyoderma gangrenosum in one 
patient [59-61]. In contrast, cystic acne, the second cutane-
ous symptom of PAPA syndrome, does not seem as respon-
sive to IL1 and TNF blockade (unpublished observations), 
raising interesting questions about the pathogenesis of each 
of the manifestations of the disease. More clinical experience 
with PAPA syndrome should help to clarify and prioritize 
best treatment options in the face of varying symptoms in 
specific target organs. 
INSIGHTS INTO DISEASE PATHWAYS 
Il-1 and TNF--targeted therapies (so-called “biol-
ogics”) have provided a generally superior alternative to 
high-dose corticosteroids in relieving inflammatory flares of 
PAPA syndrome. However, in collective experience these 
biologics have not been consistently effective in all cases 
and do not necessarily hasten remission of all the disease 
manifestations. This may not be surprising in view of the 
evidence that PSTPIP1 likely functions in multiple bio-
chemical pathways in several immune-related cells (T cells, 
neutrophils, monocyte-derived cells, NK cells). IL-1/TNF-
 antagonists suppress innate immune mechanisms fairly 
broadly and convey significant risk of infection, a particu-
larly troublesome problem when faced with managing simul-
taneous open skin lesions. Clearly, more detailed studies of 
PSTPIP1-mediated pathways are needed to better understand 
disease mechanisms in relevant tissues (i.e. joints and skin) 
and thereby inform the development of more specific thera-
pies. Genetic studies in appropriate animal models will likely 
be invaluable to these efforts. Meanwhile studies in patient 
cells have provided some initial insights. A recent study of 
macrophages cultured from monocytes of four PAPA syn-
drome patients (with confirmed A230T or E250Q mutations) 
revealed deficiencies in chemotaxis and invasive migration. 
In contrast, impairment of these functions was not observed 
in similar tests of patient T cells. In addition, PAPA syn-
drome macrophages formed significantly fewer podosomes 
than controls, and podosome structures were altered in that 
they contained increased numbers of focal complexes [62]. 
This is consistent with expression data revealing increased 
transcript levels in PAPA individuals for proteins involved in 
focal adhesion complexes (e.g. gelsolin, integrin-beta3, talin, 
PTP-PEST) [our unpublished observations]. The authors also 
noted that the dismorphology of macrophages observed in 
PAPA syndrome is reminiscent of that seen in Wiskott-
Aldrich Syndrome, suggesting a common PSTPIP1/WASP 
pathway is disrupted in both diseases, at least in mono-
cytes/macrophages. It was further hypothesized that the dra-
matic recruitment of neutrophils during PAPA syndrome 
flares is a response to signaling from macrophages retained 
in affected sites [62]. Certainly prior studies of patient pe-
ripheral blood leukocytes and serum suggest a gain-of-
function, pro-inflammatory state in these tissues, as evi-
 
Fig. (3). Schematic depiction of the “inflammasome.” IL-1 and IL18 are substrates for caspase.  524    Current Genomics, 2010, Vol. 11, No. 7  Smith et al. 
denced by overproduction of IL-1 and TNF-, and the 
original ~160 kd “streaking leukocyte factor” that stimulated 
random migration of normal neutrophils and mononuclear 
cells in vitro [18].  
Although cutaneous involvement is variable in PAPA 
syndrome it is a particularly troubling feature of the disease, 
not only in terms of clinical management but also cosmesis. 
Regarding the latter, some PAPA syndrome patients become 
quite reclusive because of concerns about their appearance. 
Pyoderma gangrenosum (and cystic acne) are characterized 
by neutrophil infiltration; given the strong PSTPIP1 expres-
sion in neutrophils we hypothesize that this is at least in part 
secondary to an intrinsic mechanism in these cells. Recent 
cell transfection studies by Cooper et al. found that PSTPIP1 
localizes to the neutrophil uropod and alters motility and 
endocytosis. However, A230T and E250Q mutants did not 
alter these functions, and thus, the role of disease mutations 
in neutrophil behavior is unresolved [42]. As noted, 
PSTPIP1 pathways in non-myeloid cells such as T cells may 
also factor in PAPA syndrome.  
Global gene expression analysis has proved to be a useful 
tool for dissecting underlying pathways in blood of patients 
with various inflammatory diseases [63-67]. This approach 
has been particularly powerful as a molecular diagnostic tool 
for certain complex diseases with relatively non-specific 
features, such as SoJIA. Like PAPA syndrome, SoJIA is an 
auto-inflammatory disease marked by overproduction of IL-
1. Gene expression in blood of SoJIA and PAPA shows 
extensive overlaps (our unpublished observations), yet So-
JIA predictive genes can distinguish it from PAPA [66]. Our 
preliminary observations of gene expression in peripheral 
blood mononuclear cells of PAPA patients using modular 
analyses have revealed strongest up-regulation of genes ex-
pressed in low-density neutrophils as well as in platelets and 
myeloid cells (Modules 2.1, 1.2, and 1.5, respectively, Fig. 
4). As examples, over-expressed neutrophil-related genes 
included defensin A4 (DEFA4), peptidyl arginine deiminase 
14 (PAD14), lipocalin 2 (LCN2), and forkhead box O3A 
(FOXO3A) among others. In addition, genes involved in 
cytotoxic cell functions were strongly under-expressed rela-
tive to controls (Fig. 4). Over-expression of neutrophil-
related genes in PBMC fractions has been observed in other 
inflammatory diseases such as SLE and SoJIA and may indi-
cate over-representation of neutrophil precursors in PAPA 
blood, although further study is required to determine this.  
SUMMARY 
The convergence of biochemical, cell biological, molecu-
lar genetic, and clinical studies in various experimental sys-
tems has brought PAPA syndrome (and afflicted patients) 
out of obscurity, clearly revealing causation and pathways to 
therapy. It has also raised intriguing new questions. The 
classification of PAPA syndrome as an inflammasomopathy 
implies a pro-inflammatory state with heightened response to 
environmental triggers. If so, are patients protected from 
generalized infections? This is difficult to determine from 
limited patient studies but an interesting concept to explore, 
perhaps in animal models. The disease pathogenesis of 
PAPA syndrome may be explained by the mutations in 
PSTPIP1 that alter its interaction with pyrin and the inflam-
masome. Alternatively, is pyroptosome formation and cell 
death relevant in vivo, for patients with PAPA syndrome? 
Either way, an apparent consequence of this is an overpro-
duction of active IL-1. In this scenario, are there specific 
microbial pathogens, other stimuli, or simply trauma that 
provoke an exuberant response and consequent flares? It will 
 
Fig. (4). Modular analyses of PAPA blood gene expression reveals over-expression of neutrophil and platelet-related genes. mRNA expres-
sion level differences in PBMCs between PAPA patients and age- and sex-matched healthy controls were obtained by statistical group com-
parison. We further performed modular analyses as described in [67, 68]. Briefly, genes are assigned a priori to particular functional units  
(i. e. modules) as derived from extensive analyses of expression in PBMCs. Statistical comparisons are then made between disease groups 
and healthy groups on a module-by-module basis, where the proportion of under- or over-expressed genes in the module is depicted in the 
cartoon by differences in color and intensity. This approach simplifies analysis and produces a distinct “fingerprint” of disease. A complete 
list of differentially expressed gene transcripts in PAPA syndrome individuals versus controls is available upon request. Clinical, Molecular, and Genetic Characteristics of PAPA Syndrome  Current Genomics, 2010, Vol. 11, No. 7    525 
be particularly important to investigate these mechanisms 
not only for sterile compartments (i.e. joints) but also in the 
skin, where interactions with comensal and pathogenic mi-
crobes abound [3]. Given the localization of PSTPIP1 along 
microtubules and its association with pyrin, why is colchi-
cine ineffective in treating for PAPA syndrome patients? As 
PSTPIP1 is a cytoskeletal protein, could it regulate IL1 
secretion rather than activation? Therapies targeting IL1 
also lack efficacy in some individuals. Could this be ex-
plained by upregulation of interleukin 18, which is also acti-
vated by the inflammasome, in PAPA patients? Finally, as 
with virtually all Mendelian disorders the variability in dis-
ease severity even within single families is baffling. The 
emerging era of whole genome sequencing may provide the 
opportunity to identify genetic modifiers that will truly en-
lighten interventions for episodic diseases such as PAPA 
syndrome.  
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